OrbiMed Advisors LLC Reports 9.99% Stake in Xilio Therapeutics, Inc.

On May 15, 2026, OrbiMed Advisors LLC filed a Schedule 13G regarding its holdings in Xilio Therapeutics, Inc. (XLO). The filing reports that OrbiMed Advisors LLC beneficially owns 642,000 shares of Common Stock, representing a 9.99% ownership stake in the company. This position includes holdings by OrbiMed Capital GP X LLC, which reported beneficial ownership of 481,500 shares, or 7.49% of the class. The shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. OrbiMed Advisors exercises investment and voting power over these securities through a management committee consisting of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. The event triggering this filing occurred on March 31, 2026. This represents a new significant position for the reporting persons, as the previous ownership percentage was reported as 0.0%.